Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1995-11-6
|
| pubmed:abstractText |
Twenty-one patients with advanced colorectal cancer, all previously pretreated with a fluoropyrimidine-based regimen, received oral etoposide: 100 mg/die for 21 consecutive days, every three weeks. No objective response was achieved; 6 pts had a short-lasting stabilization of their disease. Toxicity was substantial and mainly represented by myelosuppression and alopecia. Protracted administration of etoposide is inactive as second-line treatment of colorectal cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1120-009X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
246-8
|
| pubmed:dateRevised |
2009-8-4
|
| pubmed:meshHeading |
pubmed-meshheading:7562022-Administration, Oral,
pubmed-meshheading:7562022-Adult,
pubmed-meshheading:7562022-Aged,
pubmed-meshheading:7562022-Antineoplastic Agents,
pubmed-meshheading:7562022-Colorectal Neoplasms,
pubmed-meshheading:7562022-Etoposide,
pubmed-meshheading:7562022-Female,
pubmed-meshheading:7562022-Humans,
pubmed-meshheading:7562022-Male,
pubmed-meshheading:7562022-Middle Aged
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Oral etoposide as second-line chemotherapy for colorectal cancer: a GISCAD study. Gruppo Italiano Studio Carcinomi Apparato Digerente.
|
| pubmed:affiliation |
Servizio di Oncologia, Spedali Civili, Brescia, Italy.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|